MedTrace Logo

abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003

NCT05849935 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2023-08-14

No results posted yet for this study

Summary

This is a monocentric, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

Conditions

Interventions

DIAGNOSTIC_TEST

abioSCOPE

The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.

Sponsors & Collaborators

  • Avania

    collaborator INDUSTRY

  • Abionic SA

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-17
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849935 on ClinicalTrials.gov